Overview
Bi³⁺-Minocycline is a neuroprotective MDC prototype targeting trauma-induced damage within the central nervous system (CNS). Leveraging bismuth's low-toxicity anti-inflammatory properties and minocycline's neuroactive profile, the complex is tailored for repair and regeneration in spinal cord injury and neural trauma models.
Mechanism of Action
- Minocycline reduces microglial activation and apoptosis
- Bi³⁺ assists in blocking inflammatory cascades without systemic immunosuppression
- Complexation extends CNS residence time and targeting
Key Properties
- Axon regeneration potential in SCI models
- Favorable CNS pharmacokinetics
- Formulated for intrathecal or systemic delivery
Application
Therapeutic Class: CNS/Trauma
Use in neurodegenerative and traumatic injury protocols, including spinal cord lesions, TBI, and neuroinflammation syndromes.
Neuro
Axon Regeneration
Development Stage
Preclinical Evaluation
Further Information
For collaboration or early-access evaluation, contact our research team.
Contact Us